# A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Source: https://onco.cc/trials/nct05361174/  
OnCo record `nct05361174` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IOV-4001 in melanoma and non-small-cell lung cancer, run by Iovance Biotherapeutics, Inc., now recruiting.

## Summary

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer is a phase 1/2 interventional study registered as NCT05361174 by Iovance Biotherapeutics, Inc., with 53 participants planned, started 2022-07-20 and due to reach its primary completion in 2027-09. Interventions recorded: IOV-4001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05361174
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- Sponsor: Iovance Biotherapeutics, Inc.
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT05361174: https://clinicaltrials.gov/study/NCT05361174

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Iovance Biotherapeutics](https://onco.cc/companies/iovance/)

---
JSON: https://onco.cc/api/v1/entities/nct05361174.json